EN DE
Check 40,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

HIVE.TO (HIVE) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of HIVE.TO stock C$2.25, price C$2.44, that is 7.8% below the price, quality 29 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Financial Services CA · Based in US

HT HIVE.TO logo Thin data Nov 11, 2026

HIVE.TO

HIVE · TO
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Low debt
Revenue last quarter +74% vs. a year ago.
Fair value C$2.25 · Fairly valued
Expensive Growth (revenue 5y +27.5 %/yr in USD)
Quality 29/100
Loss-making · -98.5% net margin (TTM)
Negative free cash flow
Trails peers (4/11)
Narrow moat 8/100 · thin data
Thin data
Estimate

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

C$29.95 C$1.88 Fair Value C$2.25 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range C$1.88 – C$29.95 · fair‑value band C$1.69 – C$2.81 · the C$2.44 price screens above the C$2.25 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 11, 2026.

Follow HIVE.TO in your weekly email

Every Wednesday you see whether HIVE.TO is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

HIVE Digital Technologies Ltd., a technology company, builds and operates data centers powered by green energy in Bermuda, Paraguay, Sweden, and Canada. The Company operates the mining and sale of digital currencies and performance computing hosting.

Show moreShow less

It also provides infrastructure solutions, such as computational capacity to distributed networks in the blockchain industry. The company was formerly known as HIVE Blockchain Technologies Ltd. and changed its name to HIVE Digital Technologies Ltd. in July 2023.

HIVE Digital Technologies Ltd. was incorporated in 1987 and is headquartered in San Antonio, Texas.

Stock analysis

HIVE.TO (HIVE) currently trades at C$2.44, while our estimate is C$2.25, so the stock looks roughly fairly valued today (gap 8.4%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: C$1.69 (bear) to C$2.81 (bull), the price of C$2.44 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Financial Services sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

HIVE.TO reported revenue of $298M in FY2026 versus $211M in FY2022, a compound +9.0%/yr. Reported net income was −$148M in FY2026.

Key figures

Market cap C$650M (≈ $458M) Small · P/S ratio 2.11 · EPS (TTM) C$−1.80 · Net margin −49.8% · Return on equity −66.4% · Return on assets (EBIT) −6.7% (5-year average) · Operating margin −58.7% · Revenue (TTM) $331M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 65% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Financial Services peers we cover trades at −15% fair-value upside, at −8%, HIVE screens cheaper than that median.

Fair Value

Bear C$1.69 Fair Value C$2.25 Bull C$2.81
Price C$2.44 · Downside -7.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 29/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 6
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 25
Do the profits arrive as real cash?
Financial strength 70
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 3
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+158.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+41.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.5%
Start year 2021 (pandemic). Over 10 years: +7.0% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−10.3% (2020) → −39.1% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Watch HIVE, get fair value alerts →

Compare HIVE.TO with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Capital Markets · 456 stocks

Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −7.8% · Below median
Profitability
Return on assets −23.2% · Bottom 25%
Net margin (12 months) −98.5% · Bottom 25%
Operating margin (12 months) −58.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 73.5% · Top 25%
Balance sheet
Debt / equity 0.05× · Below median

Valuation Multiplesvs Capital Markets median · lower = cheaper

P/B 0.86× · Cheaper than median
P/S (12 months) 1.38× · Cheaper than median
EV/EBITDA 12.8× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)23 · sector 32
FUTURE (revenue growth)100 · sector 59
PAST (return on equity)0 · sector 32
HEALTH (low debt)98 · sector 94
DIVIDEND (yield)0 · sector 46

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Capital Markets stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Morgan Stanley MS $187.10 $260.72 +39% vs HIVE
The Charles Schwab Corporation SCHW $92.73 $117.60 +27% vs HIVE
Guotai Haitong Securities Co 601211 ¥16.21 ¥18.02 +11% vs HIVE
Nomura Holdings NMR $9.62 $10.17 +6% vs HIVE
The Goldman Sachs Group GS $906.22 $766.86 −15% vs HIVE
CITIC Securities Company 600030 ¥25.53 ¥20.42 −20% vs HIVE
Robinhood Markets, Inc HOOD $83.32 $47.60 −43% vs HIVE
Macquarie Group MQG A$251.54 A$123.84 −51% vs HIVE
East Money Information Co 300059 ¥18.78 ¥6.72 −64% vs HIVE
Interactive Brokers Group IBKR $77.57 $17.48 −77% vs HIVE

Explore undervalued stocks

More undervalued Financial Services stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

HIVE.TO: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "HIVE.TO Fair Value". https://www.fairvalue-calculator.com/stock/HIVE

Frequently asked questions

Is HIVE.TO (HIVE) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is C$2.25 versus a price of C$2.44, about 8% lower (fairly valued).
What is the fair value of HIVE?
Our estimate for HIVE.TO is C$2.25 (as of Nov 11, 2026), built from audited fundamentals. The current price: C$2.44.
What is the quality score of HIVE?
HIVE.TO has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for HIVE.TO (HIVE)?
Our calculated price target is the estimate of C$2.25 (as of Nov 11, 2026). Cautious scenario C$1.69, optimistic scenario C$2.81. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the HIVE.TO stock forecast for 2026?
Our estimate puts fair value at C$2.25, about 8% lower versus a price of C$2.44 (fairly valued). Cautious scenario C$1.69, optimistic scenario C$2.81. The calculation is refreshed regularly with new filings.
What is the revenue of HIVE.TO (HIVE)?
HIVE.TO reported trailing-twelve-month revenue of about $331M (latest available figure, as of Nov 11, 2026).
What is the intrinsic value of HIVE.TO (HIVE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For HIVE.TO it is C$2.25 per share (as of Nov 11, 2026), against a price of C$2.44.
Is HIVE.TO stock overvalued or undervalued in 2026?
As of Nov 11, 2026, HIVE trades above its calculated fair value: price C$2.44, fair value C$2.25, a gap of about −8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HIVE?
No. The price is what the market pays today (C$2.44); the fair value is what the company's own numbers justify (C$2.25). For HIVE.TO the two are C$0.1900 per share apart. That gap is exactly why we show both numbers side by side.
How much is HIVE.TO worth?
The market values HIVE.TO at about C$650M (market capitalisation, as of Nov 11, 2026). Per share that is C$2.44; our models calculate a fair value of C$2.25 per share.
What do the bullish and bearish scenarios say about HIVE?
Our models span a range for HIVE.TO: cautious scenario C$1.69, base C$2.25, optimistic C$2.81 per share (as of Nov 11, 2026, price C$2.44). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of HIVE.TO (HIVE)?
Balance-sheet figures for HIVE.TO (as of Nov 11, 2026): return on equity −66.4%, debt of 0.05 per unit of equity. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is HIVE from its 52-week high?
HIVE.TO trades at C$2.44, about 65% below its 52-week high of C$6.93 and 6% above the low of C$2.30 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of C$2.25 is for.
Which stocks are comparable to HIVE.TO?
From the same area (Financial Services) we also value Morgan Stanley, The Goldman Sachs Group, The Charles Schwab Corporation, Interactive Brokers Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is HIVE.TO stock attractive at the current price?
The data as of Nov 11, 2026: price C$2.44, calculated fair value C$2.25 (−8%), Quality Score 29/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.2% above its aggregate fair value. HIVE.TO itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of HIVE.TO (HIVE)?
The closing price on Nov 10, 2026 was C$2.44. Our estimate is C$2.25, about 8% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with HIVE.TO right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.

Key figures of HIVE.TO

How large is the market capitalisation of HIVE.TO (HIVE)?
The market capitalisation of HIVE.TO is C$650M (≈ $458M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of HIVE.TO (HIVE)?
The price-to-sales ratio of HIVE.TO is 2.11 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of HIVE.TO (HIVE)?
Earnings per share at HIVE.TO are C$−1.80. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of HIVE.TO (HIVE)?
The net margin of HIVE.TO is −49.8% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of HIVE.TO (HIVE)?
The return on equity (ROE) of HIVE.TO is −66.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of HIVE.TO (HIVE)?
On an EBIT basis the return on assets of HIVE.TO is −6.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of HIVE.TO (HIVE)?
The operating margin of HIVE.TO is −58.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at HIVE.TO (HIVE)?
Revenue at HIVE.TO is growing +73.5% versus a year earlier (3y avg +41.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does HIVE.TO (HIVE) generate?
The free cash flow of HIVE.TO is −$116M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does HIVE.TO (HIVE) carry?
The net debt of HIVE.TO is $48.0M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Continue in the live analysis

Fair value and trend for 40,000+ stocks, watchlist, comparison and the diversification check.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.